In 2010 OCT was awarded with the multicenter randomized open-label trial by a leading Russian pharmaceutical company. We enrolled 76 patients with this disease. The study was placed in 14 centers in Russia and Belarus. OCT has a database of over 100 oncology sites in the region where we can place the oncology trials, and we have proven track record of successfully completed studies in this therapeutic area.
The primary aim of this particular study was to assess clinical safety and therapeutic efficacy of the investigational drug, as well as to demonstrate pharmacokinetic and pharmacodynamics equivalence. OCT team has a wide experience not only in this indication, but also in other Oncology diseases, such as:
The incidence of colorectal cancer (CRC) in Russia is the highest among the BRIC (Brazil, Russia, India, China) markets and is comparable to that of the UK and the United States. Colorectal cancer is the third most commonly diagnosed cancer and the third leading cause of cancer death both for men and women in the US. But it is important to point out that the majority of deaths can be prevented if we apply existing knowledge about cancer prevention, and if all patients receive treatment in time. In the world the mean age of people diagnosed colorectal cancer is 69 years old for men and 73 for women (90% of cases occur in people 50 years and older).
In Russia 20 years ago this illness was the 6th on the list of oncological diseases, but unfortunately, today it is on the 3rd place. Regular screening helps early detection – treatment is the most effective. Sometimes screening can help to prevent colorectal cancer by removing polyps before they become cancer. People with a first-degree relative who has a colorectal cancer have 2-3 times higher risk of developing the same disease. That is why a screening could help not only the patients, but their relatives as well.